Combination of fludarabine (FAMP) cyclophosphamide (CTX) and alemtuzumab for patients with relapsed chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Tedeschi, A
Montillo, M
Miqueleiz, S
Draisci, M
Ricci, F
Scarpati, B
Mura, ME
Crugnola, M
Morra, E
机构：
[1] Univ Parma, Hematol & Transplant Unit, I-43100 Parma, Italy
[2] Osped Niguarda Ca Granda, Dept Pathol, Milan, Italy
[3] Osped Niguarda Ca Granda, Lab Transplant Immunol, Milan, Italy
[4] Osped Niguarda Ca Granda, Dept Hematol, Milan, Italy
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5036
引用
收藏
页码：341B / 341B
页数：1
相关论文
共 50 条
  • [31] Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL.
    Wierda, W
    O'Brien, S
    Ferrajoli, A
    Faderl, S
    Kornblau, SM
    Andreef, M
    Koller, C
    Garcia-Manero, G
    Thomas, D
    Kantarjian, H
    Keating, M
    BLOOD, 2003, 102 (11) : 360B - 360B
  • [32] Pilot study of fludarabine (F), cyclophosphamide (C), and amifostine (A) (FCA) in patients with chronic lymphocytic leukemia (CLL).
    Keating, AR
    O'Brien, SM
    Cortes, JE
    Thomas, D
    Koller, C
    Beran, M
    Kantarjian, HM
    Keating, MJ
    Giles, FJ
    BLOOD, 1999, 94 (10) : 313A - 313A
  • [33] A UK Cost-Effectiveness Analysis Comparing First Line Treatment with Rituximab in Combination with Fludarabine and Cyclophosphamide Versus Fludarabine and Cyclophosphamide Alone in Chronic Lymphocytic Leukemia (CLL) Patients
    Papadakis, Konstantinos
    Oscier, David
    Carr, Emma S. C.
    Lewis, Gavin
    Aultman, Rick
    BLOOD, 2008, 112 (11) : 834 - 834
  • [34] Therapy with fludarabine, cyclophosphamide and rituximab (FCR) for relapsed or untreated progressive chronic lymphocytic leukemia (CLL). A single center experience.
    Pavlovsky, Carolina
    Pavlovsky, Ntiago
    Pardo, Maria L.
    Sapia, Sandra
    Monreal, Maricla
    Corrado, Claudia
    Pavlovsky, Miguel A.
    Fernandez, Isolda
    Juni, Mariana
    BLOOD, 2006, 108 (11) : 329B - 329B
  • [35] Fludarabine with cyclophosphamide and mitoxantrone (FCM) in resistant or relapsed chronic lymphocytic leukemia (CLL):: Final results of a phase II study.
    Bosch, F
    Ferrer, A
    López-Guillermo, A
    Giné, E
    Cobo, F
    Perales, M
    Esteve, J
    Villamor, N
    Colomer, D
    Bellosillo, B
    Ribera, JM
    Altes, A
    Besalduch, J
    Montserrat, E
    BLOOD, 2001, 98 (11) : 634A - 634A
  • [36] Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia
    Feugier, Pierre
    Aurran, Therese
    Mahe, Beatrice
    Letestu, Remi
    Nguyen-Khac, Florence
    Cazin, Bruno
    Tournilhac, Olivier
    Maisonneuve, Herve
    Casasnovas, Olivier
    Delmer, Alain
    Leblond, Veronique
    Royer, Bruno
    Corront, Bernadette
    Chevret, Sylvie
    Delepine, Roselyne
    Vaudaux, Sandrine
    Van den Neste, Eric
    Bene, Marie-Christine
    Cymbalista, Florence
    Ross-Weil, Damien
    Lepretre, Stephane
    HAEMATOLOGICA, 2018, 103 (07) : E304 - E306
  • [37] A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, Rituximab combination (FCR) in chronic lymphocytic leukemia (CLL).
    Keating, M
    Manshouri, T
    O'Brien, S
    Wierda, W
    Kantarjian, H
    Washington, L
    Lerner, S
    Albitar, M
    BLOOD, 2002, 100 (11) : 205A - 205A
  • [38] Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients
    Montillo, Marco
    Tedeschi, Alessandra
    Gaidano, Gianluca
    Coscia, Marta
    Petrizzi, Valeria Belsito
    Orlandi, Ester
    Cascavilla, Nicola
    Ghia, Paolo
    Motta, Marina
    Gallamini, Andrea
    Frustaci, Anna Maria
    Rossi, Davide
    De Paoli, Lorenzo
    Nichelatti, Michele
    Morra, Enrica
    Massaia, Massimo
    HAEMATOLOGICA, 2014, 99 (09) : E159 - E161
  • [39] THE COMBINATION OF LOW DOSES FLUDARABINE & CYCLOPHOSPHAMIDE AS FRONTLINE TREATMENT FOR ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Pierri, I.
    Olcese, F.
    Cagnetta, A.
    Bergamaschi, M.
    Gobbi, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 527 - 527
  • [40] Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
    Parikh, Sameer A.
    Keating, Michael J.
    O'Brien, Susan
    Wang, Xuemei
    Ferrajoli, Alessandra
    Faderl, Stefan
    Burger, Jan
    Koller, Charles
    Estrov, Zeev
    Badoux, Xavier
    Lerner, Susan
    Wierda, William G.
    BLOOD, 2011, 118 (08) : 2062 - 2068
12345